Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors

Angiogenesis, the formation of new blood vessels from a pre-existing vasculature, is tightly regulated in normal adults. Under physiological circumstances, angiogenesis occurs in only a few instances; e.g., the female reproductive system in response to ovulation or gestation, the normal hair cycle, etc. In these examples, growth of new capillaries is tightly controlled by an interplay of growth regulatory proteins which act either to stimulate or to inhibit blood vessel growth. Normally, the balance between these forces is tipped in favor of inhibition and consequently capillary growth is restrained. Under certain pathological circumstances, however, local inhibitory controls are unable to restrain the increased activity of angiogenic inducers. Thus, in wound healing, inflammation and tumors, to name just a few examples, angiogenesis is integral to the pathology, engendering the hope that these pathological entities could be regulated by pharmacological and/or genetic suppression (or enhancement) of blood vessel growth. This hope, in turn, has fostered interest in the molecular mechanisms that regulate angiogenesis. In this chapter, we have reviewed the current literature regarding some angiogenic stimulators and inhibitors, emphasizing vascular permeability factor (VPF, also known as vascular endothelial growth factor or VEGF), as a major angiogenic inducer, and thrombospondin (TSP) as the best known example of a natural inhibitor of vessel growth.

[1]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[2]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[3]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[4]  Harold E. Dvorak,et al.  Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin , 1996, The Journal of experimental medicine.

[5]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[6]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[7]  P. Porter,et al.  Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. , 1996, The Journal of clinical investigation.

[8]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[9]  J. Rossant,et al.  The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. , 1995, The EMBO journal.

[10]  M. Reed,et al.  Expression of thrombospondins by endothelial cells. Injury is correlated with TSP-1. , 1995, The American journal of pathology.

[11]  Thomas N. Sato,et al.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.

[12]  K. Alitalo,et al.  Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.

[13]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[14]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[15]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[16]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[17]  Thomas N. Sato,et al.  Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Iwama,et al.  Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cells. , 1993, Biochemical and biophysical research communications.

[19]  O. Volpert,et al.  Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity , 1993, The Journal of cell biology.

[20]  C. Disteche,et al.  Isolation and characterization of the mouse thrombospondin 3 (Thbs3) gene. , 1993, Genomics.

[21]  J. Lawler,et al.  Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family , 1993, Journal of Cell Biology.

[22]  D. Heinegård,et al.  COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. , 1992, The Journal of biological chemistry.

[23]  H. Dvorak,et al.  Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[24]  P. Bornstein,et al.  Thrombospondins: structure and regulation of expression , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  L. Leung,et al.  CD36 peptides enhance or inhibit CD36-thrombospondin binding. A two-step process of ligand-receptor interaction. , 1992, The Journal of biological chemistry.

[26]  J. Rossant,et al.  tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. , 1992, Oncogene.

[27]  P. Bornstein,et al.  Thrombospondin 3 (Thbs3), a new member of the thrombospondin gene family. , 1992, The Journal of biological chemistry.

[28]  H. Krutzsch,et al.  Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin promote melanoma cell adhesion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Disteche,et al.  Thrombospondin II: partial cDNA sequence, chromosome location, and expression of a second member of the thrombospondin gene family in humans. , 1992, Genomics.

[30]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  F. W. Wolf,et al.  A second, expressed thrombospondin gene (Thbs2) exists in the mouse genome. , 1991, The Journal of biological chemistry.

[32]  V. Dixit,et al.  Human carcinoma cells bind thrombospondin through a Mr 80,000/105,000 receptor. , 1991, Cancer research.

[33]  M. Iruela-Arispe,et al.  Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Ingber,et al.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.

[35]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Moses,et al.  Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane , 1990, The Journal of cell biology.

[37]  P. Bagavandoss,et al.  Specific inhibition of endothelial cell proliferation by thrombospondin. , 1990, Biochemical and biophysical research communications.

[38]  R. Boot-Handford,et al.  Thrombospondin gene expression by endothelial cells in culture is modulated by cell proliferation, cell shape and the substratum. , 1990, The Biochemical journal.

[39]  G. Tuszynski,et al.  The interaction of thrombospondin with platelet glycoprotein GPIIb-IIIa. , 1989, The Journal of biological chemistry.

[40]  M. Höök,et al.  Thrombospondin modulates focal adhesions in endothelial cells , 1989, The Journal of cell biology.

[41]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[42]  Peter J. Polverini,et al.  Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene , 1989, Cell.

[43]  R. Hynes,et al.  Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors , 1988, The Journal of cell biology.

[44]  H. Dvorak,et al.  Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[45]  J. Barnwell,et al.  Isolation of the thrombospondin membrane receptor. , 1987, The Journal of clinical investigation.

[46]  M. Takigawa,et al.  A factor in conditioned medium of rabbit costal chondrocytes inhibits the proliferation of cultured endothelial cells and angiogenesis induced by B16 melanoma: its relation with cartilage-derived anti-tumor factor (CATF). , 1987, Biochemistry international.

[47]  J. Fiddes,et al.  Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth , 1987, Nature.

[48]  P. Bornstein,et al.  Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[49]  H. Dvorak,et al.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. , 1986, Cancer research.

[50]  P. Hi Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors. , 1986 .

[51]  G. Giménez-Gallego,et al.  Fibroblast growth factors: broad spectrum mitogens with potent angiogenic activity , 1986 .

[52]  J. Folkman,et al.  Protamine is an inhibitor of angiogenesis , 1982, Nature.

[53]  J. Vacanti,et al.  Control of tumor growth in animals by infusion of an angiogenesis inhibitor. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[54]  E. Manseau,et al.  Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. , 1979, Journal of the National Cancer Institute.

[55]  R. Langer,et al.  Isolations of a cartilage factor that inhibits tumor neovascularization. , 1976, Science.

[56]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. , 1997, EXS.

[57]  D. Maglione Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor , 1991 .

[58]  D. Mosher Physiology of thrombospondin. , 1990, Annual review of medicine.

[59]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[60]  H. Peterson Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors. , 1986, Anticancer Research.